Decentralized Trial Tech Stack for Cardiovascular Outcomes Studies

Why CVOTs Stretch DCT Technology Distinctively

Cardiovascular outcomes trials are structurally different from most other clinical trials in three ways that matter for technology architecture.

First, they are very large. A 12,000-patient CVOT generates orders of magnitude more data per visit than a 300-patient phase 2 trial, and the data flow is sustained over years rather than months. The tech stack must scale not just to peak load but to sustained load over the trial duration.

Second, they are very long. A 5-6 year duration means the technology choices made at study start must remain operationally viable through the end of the study, even as vendor markets evolve, platforms get acquired, and patient devices change generation. Vendor durability and platform stability matter more in CVOTs than in shorter studies.

Third, the primary endpoints are event-driven and require adjudication. MACE events — cardiovascular death, nonfatal MI, nonfatal stroke, hospitalization for unstable angina — are reported by sites, captured by the EDC, and adjudicated by an independent committee. The technical workflow that supports this adjudication is more elaborate than the workflow that supports a simple continuous endpoint study.

Adding decentralized elements to a CVOT compounds these challenges. Remote visits must integrate into the longitudinal patient record across years. Connected devices must produce data that supports event detection without overwhelming the adjudication committee. Patient-reported outcomes must be collected reliably from patients who may move, change phones, or lose engagement over multi-year follow-up. The tech stack choices that work in shorter, smaller studies often do not scale; this article focuses on the choices that do.

The Stack Architecture That Holds Up at Scale

The tech stack architecture that holds up at CVOT scale has four layers, each with specific requirements that derive from the CVOT operational profile.

Data ingestion layer. Connected devices, ePRO/eCOA, remote visit data, in-person visit data, central laboratory data, and adjudication committee data all flow into a single ingestion layer that normalizes, time-stamps, and audit-trails each input. The ingestion layer must be vendor-agnostic enough to accommodate device changes over the trial duration without requiring full re-architecture. This is a meaningful constraint; tightly coupled vendor architectures that work in short trials produce reconfiguration debt in long trials.

Patient longitudinal record layer. Every data input is keyed to the patient and time-stamped, producing a longitudinal record that persists for the patient across years. The longitudinal record must support both real-time monitoring (for safety surveillance) and database lock (for primary analysis). The architecture choice that affects this most is whether the longitudinal record is a derived view from underlying transactional stores or a primary persistent store; both work but have different operational characteristics.

Endpoint detection and adjudication layer. Potential MACE events are flagged from the longitudinal record using rule-based and (increasingly) AI-assisted detection. Flagged events trigger an adjudication workflow that routes documentation to the independent committee, captures committee decisions, and feeds the adjudicated outcomes back to the trial database. The detection and adjudication layer is the heart of the CVOT operational technology stack; the rest of the stack supports it.

Operational monitoring and oversight layer. Sponsor, CRO, and DSMB monitoring of trial conduct uses dashboards and alerts built on the longitudinal record. The monitoring layer must serve different audiences (operational team, medical monitor, DSMB) with appropriately scoped views, and the audit trail across these views must hold up at inspection.

Connected Devices and Cardiac Monitoring

Connected devices are the most visible decentralized element in modern CVOTs. The devices include wrist-worn wearables, chest-worn patches, smartphone-based ECG (e.g., AliveCor / KardiaMobile-class devices), connected blood pressure cuffs, connected glucose monitors (in studies that include diabetes context), and increasingly implanted devices that stream telemetry. The stack must accommodate all of these without requiring patients to manage multiple separate apps.

The pattern that works in 2025-2026 CVOTs is a consolidated patient app that integrates with multiple device classes through standard APIs (HealthKit, Google Fit) and direct device manufacturer integrations. The patient sees one app; the trial team sees one normalized data stream. The vendor that supplies the patient app may not supply the underlying devices, which is appropriate because device markets evolve faster than the trial duration.

The technical challenge with cardiac monitoring at scale is signal quality. Wearables and patches produce many false positives at the population level: a 10,000-patient population wearing continuous monitors for years will generate hundreds of thousands of arrhythmia flags, the vast majority of which are not true events. The stack must filter these effectively without missing true events, which requires a multi-tier triage workflow: device-level filtering, central monitoring filtering, clinician review, and adjudication committee escalation only for events that meet pre-specified criteria.

The FDA’s DCT guidance and digital health technology guidance reinforces the expectation that connected device data be of demonstrated quality and integrity, with documented validation appropriate to the intended use. For CVOTs, this expectation translates into a documented validation strategy for each device class, demonstrating that the device produces data of sufficient quality to support its specific role in the endpoint detection workflow.

Remote Endpoint Adjudication Workflows

Endpoint adjudication in CVOTs has historically been a paper-and-mail process: the site produces a packet of source documents, the CRO assembles the adjudication package, the package is mailed to the independent committee members, and the committee meets to adjudicate. This process scales poorly to large CVOTs and is being modernized in essentially all current CVOT designs.

The remote adjudication workflow that works in 2025-2026 CVOTs has five elements. First, source documents are uploaded by sites through a secure portal rather than mailed. Second, the adjudication package is assembled algorithmically from the uploaded sources rather than manually. Third, committee members review packages through a secure platform that captures their adjudication decisions structurally. Fourth, the platform routes packages to committee members based on workload balance and conflict-of-interest screening. Fifth, adjudication decisions feed back into the trial database with full audit trail.

The platform choice matters at scale. A platform that works for a 200-event adjudication committee may not work for a 2,000-event committee. The stack must scale the workflow, manage the document load, and preserve the independence and blinding of the adjudication. Major sponsors typically use specialized adjudication platforms supplied by vendors with CVOT-specific experience, because the workflow is sufficiently specialized that general-purpose document review platforms underperform.

Long-Duration Data Integrity Considerations

The 5-6 year duration of a CVOT introduces data integrity considerations that are absent or muted in shorter trials. Three matter most.

Patient identifier continuity across device generations. A patient who enrolls in 2026 wearing a current-generation wearable may, over five years, transition through two or three device generations. The patient identifier must persist across these transitions, the data must remain attributable to the patient through each transition, and the audit trail must document the transitions. Programs that fail this often discover the failure only at database lock, when the longitudinal record turns out to have gaps or attribution errors.

Vendor durability and continuity planning. Vendors that work at study start may be acquired, may exit the market, or may sunset specific product lines over the trial duration. The stack should be designed so that any single vendor exit can be accommodated without compromising the longitudinal record. This typically means avoiding tight vendor lock-in, maintaining export-ready data formats, and including continuity provisions in vendor contracts.

Audit trail persistence and integrity over years. The audit trail for a 5-year CVOT must remain accessible, queryable, and forensically intact through database lock and any subsequent regulatory submissions or inspections. This sounds trivial but is operationally non-trivial: vendor platforms upgrade, formats evolve, and storage infrastructure changes. Programs that fail to plan for audit trail persistence often discover the failure at submission or inspection, by which point remediation is expensive.

The ICH E6(R3) and broader ICH efficacy guidelines reinforce the long-duration data integrity expectations through their formal articulation of ALCOA+ principles. CVOT designs that explicitly map their tech stack against these principles, including over multi-year operation, produce documentation that holds up at inspection materially better than designs that treat data integrity as a steady-state property only.

Regulatory Overlay for Cardiovascular Outcomes

Cardiovascular outcomes trials operate under a regulatory overlay that is specific to the indication. The FDA’s CV safety expectations for diabetes drugs, the post-marketing requirements for certain cardiovascular agents, and the historical CVOT precedents shape the regulatory expectations for CVOT design and conduct.

The DCT-specific regulatory overlay is layered on top. The FDA’s DCT guidance and the EMA’s decentralised clinical trials guidance apply to CVOTs as they do to other studies. The technology stack must satisfy both the CVOT-specific expectations and the broader DCT expectations.

The intersection is straightforward in principle and demanding in practice. Connected device data must be of demonstrated quality to support cardiovascular endpoint detection. Remote visits must preserve the integrity of cardiovascular assessments. Patient-reported outcomes collected remotely must be validated against in-person collection. Endpoint adjudication must remain independent and blinded regardless of the digital workflow. The technical architecture must support all of these expectations through database lock and beyond.

Sponsors planning CVOTs in 2026 should expect to engage with FDA’s DCT-experienced reviewers as well as the cardiovascular-experienced reviewers, and to demonstrate that the DCT elements do not compromise the trial’s ability to support the cardiovascular outcome claim. Pre-submission meetings on DCT elements are highly encouraged for CVOTs, both because of the trial scale and because of the regulatory weight of the outcome.

Sponsor Playbook for 2026 CVOT Designs

For sponsors designing CVOTs in 2026, the operational playbook drawn from the 2024-2025 cohort has six elements.

1. Design the data ingestion layer for vendor evolution. Assume that at least one major vendor will change over the trial duration. Build the ingestion layer to accommodate this without requiring re-architecture.

2. Select the adjudication platform during protocol finalization. The adjudication workflow is too consequential to defer. Selecting the platform, validating it against expected event volume, and documenting it in the protocol prevents downstream operational problems.

3. Plan the connected device strategy as a multi-tier triage. Device-level filtering, central monitoring filtering, clinician review, adjudication escalation — each tier should have defined criteria. The strategy should be documented in the trial protocol or operational plan.

4. Engage FDA’s DCT-experienced reviewers early. The intersection of CVOT and DCT raises specific questions that benefit from pre-submission discussion. Programs that defer this engagement until submission encounter avoidable friction.

5. Plan for long-duration audit trail persistence. The audit trail must be queryable through database lock and any subsequent inspections, which may occur years after study start. Vendor contracts, storage architecture, and export readiness should all be designed for this duration.

6. Build the patient retention strategy into the tech stack design. Patient attrition over 5-6 years is one of the largest risks in a CVOT. The patient app, remote visit workflow, and engagement design should explicitly support retention, not just data collection. Endpoints News and BioPharma Dive have documented multiple high-profile CVOTs where retention challenges materially affected outcomes; planning for retention as a tech stack concern is overdue in many programs.

The 2024-2025 CVOT cohort has demonstrated that DCT elements can be incorporated into large outcomes trials successfully. The operational architecture is recognizable; the stack choices are defined; the regulatory overlay is understood. 2026 designs that build deliberately against this template will move materially faster and produce more defensible trial conduct than designs that improvise.

References & Sources